What is PlateletBio?
Founded in 2014, PlateletBio operates at the intersection of advanced biotechnology and cell therapy. The company has established a robust platform designed to harness the potential of platelet-based therapies, aiming to address significant unmet needs in patient care. By focusing on the development of scalable, off-the-shelf cell therapies, PlateletBio distinguishes itself from traditional therapeutic approaches, offering a novel mechanism for treating various hematological and immunological conditions. Its market position is bolstered by a commitment to rigorous scientific validation and a strategic focus on high-impact clinical applications, making it a key player in the evolving regenerative medicine sector.
How much funding has PlateletBio raised?
PlateletBio has raised a total of $75.5M across 1 funding round:
Series B
$75.5M
Series B (2021): $75.5M with participation from K2 HealthVentures, Ziff Capital Partners, Qiming Venture Partners, Oxford Finance, and SymBiosis
Key Investors in PlateletBio
K2 HealthVentures
K2 HealthVentures is an alternative investment firm providing flexible, long-term financing solutions to innovative companies within the life sciences and healthcare sectors.
Qiming Venture Partners
Qiming Venture Partners is a prominent venture capital firm that supports innovative startups across technology and healthcare by providing strategic guidance and industry resources.
Oxford Finance
Oxford Finance is a specialty finance firm that offers tailored financial solutions and capital support to healthcare and life sciences companies globally.
What's next for PlateletBio?
With the successful closure of this major strategic investment, PlateletBio is poised to accelerate its R&D initiatives and expand its clinical trial footprint. The company's roadmap likely includes the optimization of its manufacturing processes to support larger-scale therapeutic production and the advancement of its lead candidates through regulatory milestones. As the firm enters this next phase of growth, the focus will shift toward demonstrating clinical efficacy and establishing long-term value for stakeholders. The backing from a diverse syndicate of life sciences investors provides not only the financial stability required for long-term development but also the strategic guidance necessary to navigate the complexities of the global biotechnology market.
See full PlateletBio company page
